Nantes, on 15 may 2017, 18 hours, 15 – DARE Immunotherapeutics AG (ISIN: FR0012127173; Mnémo: OSE), announced that the company has introduced in the session of oral significant data on its selective antagonist SIRPa, DARE-172 (Effi-DEM), to the 2nd edition of the congress “Advances in Immuno-Oncology” in London on may 15, 2017.
Download the free guide
Boost your gains
DARE-172 (Effi-DEM) is a monoclonal antibody targeting the receptor SIRPa, is expressed on cells of the myeloid suppressive (” MDSC “, Myeloid-Derived Suppressive Cells, and ” TAM, Tumor-Associated Macrophages, myeloid cells and effector macrophages (antitumor), involved in the tumor microenvironment. Selective antagonist of SIRPa, DARE-172 promotes the recruitment of myeloid cells to effector to the detriment of cells of the myeloid suppressive, in particular, it inhibits macrophage cells M2 pro-tumor and increases the macrophage cells M1 anti-tumor, while increasing the effector cells are CD8 ( + ) T memory.
DARE-172 does not have a link with red blood cells and human platelets, which is an advantage in the haematological potential in terms of tolerance.
In addition, OSE-172 is very selective since it does not target that SIRPa and that it is not related to human T cells (no binding to PROS -?????? expressed on T cells), thus allowing a high proliferation of these effector T cells in parallel to a blocking of cells of the myeloid suppressive. This mechanism of action of the original induced a reduction of tumor growth in several models of solid tumors, with a strong transformation of immune cells in the tumor microenvironment :
Used as monotherapy or in combination with activators of T cell responses – anti-PD-L1 (checkpoint inhibitors) or anti-41BB (receptor co-stimulators) – DARE-172 was shown to be very effective by allowing macrophages effectors, and T cells act together and reduce the size of the tumor significantly. Parallel to the transformation of myeloid cells suppressive in effector cells, the tumor microenvironment has been significantly altered with the accumulation of intra-tumour cell cytolytic NK (” Natural Killer ” cells, natural killer (nk) and B cell effector. Another interesting element was observed, the significant reduction of regulatory T cells in the periphery.
“Our checkpoint inhibitor DARE-172 has demonstrated its strong impact on the tumor microenvironment by acting on myeloid cells, taclant and cancer due to a specific blocking of SIRPa,” says Nicolas Poirier, scientific Director of OSE Immunotherapeutics.
ABOUT THE “2ND ANNUAL ADVANCES IN IMMUNO-ONCOLOGY CONGRESS”
http://www.immunooncology-congress.com/
15-16 May 2017, London
Session: Discovery of Immuno-Oncology Therapies:
Selective Anti-SIRPa: The Next Generation Checkpoint Inhibitor Targeting Pro-Tumors And Suppressors Myeloid Cells
Nicolas Poirier, Ph.D., CSO, DARE Immunotherapeutics
ABOUT DARE IMMUNOTHERAPEUTICS
Our ambition is to become one of the world leaders in immunotherapy activation and regulation
DARE Immunotherapeutics) is a biotechnology company specializing in the activation and immune regulation in immuno-oncology, autoimmune diseases and in transplantation.
The company has a balanced portfolio, with a risk profile that is diverse, ranging from the clinical phase to registration of R&D :
Immuno-oncology:
??? Tedopi®, a combination of 10 néoépitopes optimized to induce an activation response in immuno-oncology – ongoing Phase 3 registration in the lung cancer advanced in Europe and the United States, in patients with HLA-A2+ – Status orphan to the United States – Registration expected in 2020 – A Phase 2 study of Tedopi® in combination with a checkpoint inhibitor in NSCLC is planned in 2017.
??? DARE-172 (Effi-DEM), checkpoint of the new generation targeting cells of the myeloid suppressor via receptor SIRP-? – In preclinical in several cancer models.
In autoimmune diseases and transplantation :
??? FR104, immunotherapy antagonist of the CD28 – Results of Phase 1 positive – refers to autoimmune diseases, and transplantation – Licensed to Janssen Biotech Inc. for further clinical development.
??? DARE-127 (Effi-7), immunomodulatory receptor antagonist to interleukin-7 – preclinical in inflammatory bowel disease and other autoimmune diseases – Option license agreement with Servier for the development and commercialization of the product.
In the light of medical needs targeted, these products have a real potential blockbuster and make the company the ability to enter into global agreements at different stages of their development with major pharmaceutical players.
DARE Immunotherapeutics seeks the field of immunotherapy, a very attractive market in full expansion. The immunotherapy of cancer may represent to the year 2023, nearly 60% of treatments, compared to less than 3% at the present time* and the market is estimated is estimated to be $ 67 billion by 2018**.
There are more than 80 autoimmune diseases that represent an important market integrating of the major players in the pharmaceutical industry, with sales in excess of 10 billion euros for the main products. The medical need is still largely unfulfilled and will require the provision of new products to control the immune system’s innovative and responsive. *Citi Research Equity
**BCC Research
More information on http://ose-immuno.com
Download the free guide
Boost your gains
